ADVERTISEMENT
Quiz
Quiz: In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with intrahepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
11/02/2022
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement